RxDoctor Payments Data

Jared Ennis, MD

Interventional Pain Medicine · Fayetteville, ARNPI 1467539155

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,211 of the $3,706 with a category attached, or 86.6%. 13 manufacturers reported payments, led by Medtronic at 36.5% of the total. That places this record below the midpoint for interventional pain medicine clinicians in AR, where the typical reported total is $3,706.

$3,706in general payments, 2019–2025

Across 149 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$876
  • Nevro Corp.$455
  • Spinal Simplicity, LLC$307
  • Stryker$217
  • SPR Therapeutics, Inc$203
  • plus $294 from 7 others

What the payments were for

  • Travel & lodging$47613%
  • Food & beverage$3,21187%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,706 in reported general payments places this provider in the 50th percentile of 29 interventional pain medicine providers in Arkansas.

See all interventional pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$334,193
Medicare patients
397
Services billed
16,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine113$31,651
NucyntaTapentadol Hcl13$14,414
BelbucaBuprenorphine Hcl20$14,235
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen433$9,190
OxycontinOxycodone Hcl11$6,398
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen155$4,252
Gabapentin294$4,161
Pregabalin196$3,401
Tramadol Hcl221$1,880
Diclofenac Sodium51$1,059
Oxycodone Hcl46$867
Duloxetine Hcl63$825
Cyclobenzaprine Hcl85$644
Baclofen57$588
Tizanidine Hcl52$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Belbuca$66$28,64933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 29 interventional pain medicine providers in Arkansas.

Other interventional pain medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →